Cargando…
Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
Since its identification in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in 46 million cases and more than one million deaths worldwide, as of 30 October 2020. Limited data exist...
Autores principales: | Almansour, Iman, Macadato, Nabela Calamata, Alshammari, Thamer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825551/ https://www.ncbi.nlm.nih.gov/pubmed/33419184 http://dx.doi.org/10.3390/ph14010039 |
Ejemplares similares
-
Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
por: Youn, Hyewon, et al.
Publicado: (2015) -
Nucleophile responsive charge-reversing polycations for pDNA transfection
por: Lewis, Reece W., et al.
Publicado: (2023) -
Natural steroid-based cationic copolymers cholesterol/diosgenin-r-PDMAEMAs and their pDNA nanoplexes: impact of steroid structures and hydrophobic/hydrophilic ratios on pDNA delivery
por: Wang, Zhao, et al.
Publicado: (2021) -
Amino-acid functionalized porous silicon nanoparticles for the delivery of pDNA
por: Chaix, Arnaud, et al.
Publicado: (2019) -
Characterization of transgene expression and pDNA distribution of the suctioned kidney in mice
por: Oyama, Natsuko, et al.
Publicado: (2017)